3,4-Diaminopyridine

drugbox
IUPAC_name = 3,4-Diaminopyridine


width = 120
CAS_number = 54-96-6
ATC_prefix =
ATC_suffix =
PubChem =
ChemSpiderID = 5705
DrugBank =
C=5 | H=7 | N=3
molecular_weight = 109.13
bioavailability = 30% [cite journal |author=AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. |title=Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement |journal=Muscle Nerve |volume=24 |pages=1236–1238 |year=2001 |doi=10.1002/mus.1139] , [cite journal |author=Lundh H, Nilsson O, Rosen I, Johansson S. |title=Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. |journal=Acta Neurol Scand |volume=88 |pages=136–140 |year=1993]
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Phase III
routes_of_administration = Oral

3,4-Diaminopyridine is an organic compound with the formula C₅H₃N(NH₂)₂. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

Applications

3,4-Diaminopyridine experimental drug for the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca²⁺ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca²⁺ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate. It is also used to treat many of the Congenital Myasthenic Syndromes.

This compound has also been proposed for the treatment of multiple sclerosis. [cite journal |author=Judge S, Bever C |title=Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment |journal=Pharmacol. Ther. |volume=111 |issue=1 |pages=224–59 |year=2006 |pmid=16472864 |doi=10.1016/j.pharmthera.2005.10.006]

ee also

* 4-Aminopyridine

References